Core Laboratories NV (CLB) Research Coverage Started at DA Davidson
Several other equities research analysts have also recently issued reports on the stock. Loop Capital started coverage on shares of Core Laboratories NV in a research report on Friday, September 30th. They set a hold rating and a $120.00 price objective for the company. Citigroup Inc. cut their price objective on shares of Core Laboratories NV from $116.00 to $110.00 and set a neutral rating for the company in a research report on Wednesday, September 28th. Zacks Investment Research cut shares of Core Laboratories NV from a buy rating to a hold rating in a research report on Monday, September 26th. Credit Suisse Group AG started coverage on shares of Core Laboratories NV in a research report on Thursday, September 1st. They set a neutral rating and a $115.00 price objective for the company. Finally, JPMorgan Chase & Co. cut shares of Core Laboratories NV from a neutral rating to an underweight rating in a research report on Tuesday, July 12th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $121.33.
Shares of Core Laboratories NV (NYSE:CLB) opened at 113.34 on Wednesday. The stock has a market capitalization of $5.00 billion, a PE ratio of 60.13 and a beta of 1.45. The firm has a 50-day moving average of $111.18 and a 200 day moving average of $117.50. Core Laboratories NV has a 52-week low of $84.50 and a 52-week high of $135.49.
Core Laboratories NV (NYSE:CLB) last issued its earnings results on Wednesday, July 20th. The company reported $0.35 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.35. The business earned $148.10 million during the quarter, compared to analysts’ expectations of $146.37 million. Core Laboratories NV had a net margin of 11.81% and a return on equity of 344.55%. The company’s quarterly revenue was down 27.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.81 earnings per share. Equities research analysts forecast that Core Laboratories NV will post $1.54 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the company. Advisory Services Network LLC increased its position in shares of Core Laboratories NV by 33.2% in the third quarter. Advisory Services Network LLC now owns 1,062 shares of the company’s stock worth $119,000 after buying an additional 265 shares in the last quarter. Franklin Street Advisors Inc. NC bought a new stake in Core Laboratories NV during the third quarter worth $4,875,000. Telemus Capital LLC boosted its stake in Core Laboratories NV by 50.3% in the third quarter. Telemus Capital LLC now owns 22,517 shares of the company’s stock worth $2,529,000 after buying an additional 7,538 shares during the last quarter. Chevy Chase Trust Holdings Inc. bought a new stake in Core Laboratories NV during the third quarter worth $202,000. Finally, Fulton Bank N.A. boosted its stake in Core Laboratories NV by 15.2% in the third quarter. Fulton Bank N.A. now owns 2,758 shares of the company’s stock worth $310,000 after buying an additional 363 shares during the last quarter.
About Core Laboratories NV
Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.
Receive News & Ratings for Core Laboratories NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories NV and related companies with MarketBeat.com's FREE daily email newsletter.